Symbols / CRBU
CRBU Chart
About
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 200.02M |
| Enterprise Value | 78.23M | Income | -157.13M | Sales | 9.29M |
| Book/sh | 1.52 | Cash/sh | 1.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 147 | IPO | — |
| P/E | — | Forward P/E | -1.08 | PEG | — |
| P/S | 21.52 | P/B | 1.41 | P/C | — |
| EV/EBITDA | -0.58 | EV/Sales | 8.42 | Quick Ratio | 5.35 |
| Current Ratio | 5.54 | Debt/Eq | 17.95 | LT Debt/Eq | — |
| EPS (ttm) | -1.70 | EPS next Y | -1.99 | EPS Growth | — |
| Revenue Growth | 8.60% | Earnings | 2026-03-17 | ROA | -32.41% |
| ROE | -74.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -13.38% | Profit Margin | 0.00% | Shs Outstand | 93.47M |
| Shs Float | 84.50M | Short Float | 8.44% | Short Ratio | 7.08 |
| Short Interest | — | 52W High | 3.54 | 52W Low | 0.66 |
| Beta | 2.61 | Avg Volume | 1.07M | Volume | 4.61M |
| Target Price | $10.88 | Recom | None | Prev Close | $1.92 |
| Price | $2.14 | Change | 11.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.88
Mean price target
2. Current target
$2.14
Latest analyst target
3. DCF / Fair value
$-14.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.14
Low
$4.00
High
$32.00
Mean
$10.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | init | Clear Street | — → Buy | $13 |
| 2025-11-05 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-11-03 | main | Citigroup | Buy → Buy | $8 |
| 2025-04-28 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-01-07 | main | B of A Securities | Buy → Buy | $11 |
| 2024-11-26 | main | Citigroup | Buy → Buy | $6 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-07 | reit | RBC Capital | Outperform → Outperform | $14 |
| 2024-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-06-04 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-16 | main | Truist Securities | Buy → Buy | $19 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2024-03-19 | main | HC Wainwright & Co. | Buy → Buy | $24 |
| 2024-03-12 | reit | RBC Capital | Outperform → Outperform | $19 |
| 2023-11-08 | init | Cantor Fitzgerald | — → Neutral | — |
| 2023-07-26 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2023-07-14 | reit | Truist Securities | Buy → Buy | $23 |
- Insider Sale: Chief Technology Officer of $CRBU Sells 3,147 Shares - Quiver Quantitative Wed, 25 Feb 2026 02
- Caribou Biosciences CLO sold $13,598 in CRBU stock - Investing.com Wed, 25 Feb 2026 02
- Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Yahoo Finance Fri, 20 Feb 2026 21
- Caribou Biosciences CLO sold $13,598 in CRBU stock - Investing.com India Wed, 25 Feb 2026 03
- CRISPR-focused Caribou set for fireside chats at 2 investor events - Stock Titan hu, 12 Feb 2026 08
- Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - Zacks Investment Research Fri, 20 Feb 2026 15
- Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why - Yahoo Finance ue, 13 Jan 2026 08
- Khan, Caribou Biosciences CBO, sells $13598 in stock - Investing.com Wed, 25 Feb 2026 01
- Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- Caribou Biosciences CMO sells $2.1k in CRBU stock - Investing.com South Africa Wed, 25 Feb 2026 02
- Caribou Biosciences CTO Kelly sells $6.1k in shares - Investing.com South Africa Wed, 25 Feb 2026 02
- Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem - Stock Titan Wed, 04 Feb 2026 08
- Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
- Caribou Biosciences (CRBU) Is Down 7.8% After Positive Phase 1 CAR-T Data and Phase 3 Trial Plans – Has The Bull Case Changed? - Yahoo Finance hu, 06 Nov 2025 08
- Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update - Stock Titan Sun, 02 Nov 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 151700 | — | — | Stock Award(Grant) at price 0.00 per share. | HAURWITZ RACHEL E. PH.D. | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
| 1 | 55000 | — | — | Stock Award(Grant) at price 0.00 per share. | RYALI SRIRAM | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 2 | 20000 | 20400 | — | Purchase at price 1.02 per share. | HAURWITZ RACHEL E. PH.D. | Chief Executive Officer | — | 2025-03-14 00:00:00 | I |
| 3 | 3564 | 4811 | — | Sale at price 1.35 per share. | MCCLUNG BARBARA G | Officer | — | 2025-02-21 00:00:00 | D |
| 4 | 3564 | 4811 | — | Sale at price 1.35 per share. | KANNER STEVEN B. | Officer | — | 2025-02-21 00:00:00 | D |
| 5 | 3564 | 4811 | — | Sale at price 1.35 per share. | KHAN RUHI AHMAD | Officer | — | 2025-02-21 00:00:00 | D |
| 6 | 37500 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCLUNG BARBARA G | Officer | — | 2025-02-20 00:00:00 | D |
| 7 | 136750 | — | — | Stock Award(Grant) at price 0.00 per share. | HAURWITZ RACHEL E. PH.D. | Chief Executive Officer | — | 2025-02-20 00:00:00 | D |
| 8 | 37500 | — | — | Stock Award(Grant) at price 0.00 per share. | KELLY TIMOTHY P | Chief Technology Officer | — | 2025-02-20 00:00:00 | D |
| 9 | 37500 | — | — | Stock Award(Grant) at price 0.00 per share. | KANNER STEVEN B. | Officer | — | 2025-02-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -27.93K | 427.68K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -162.69M | -112.53M | -104.64M | -67.58M |
| TotalUnusualItems | -6.00K | -133.00K | 1.58M | |
| TotalUnusualItemsExcludingGoodwill | -6.00K | -133.00K | 1.58M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -149.10M | -102.07M | -99.42M | -66.92M |
| ReconciledDepreciation | 3.93M | 3.52M | 1.62M | 984.00K |
| EBITDA | -162.69M | -112.53M | -104.78M | -66.00M |
| EBIT | -166.62M | -116.06M | -106.40M | -66.98M |
| NetInterestIncome | 140.00K | |||
| InterestExpense | 8.00K | |||
| InterestIncome | 148.00K | |||
| NormalizedIncome | -149.10M | -102.07M | -99.32M | -68.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -149.10M | -102.07M | -99.42M | -66.92M |
| TotalExpenses | 176.61M | 150.54M | 120.25M | 76.58M |
| TotalOperatingIncomeAsReported | -166.62M | -116.06M | -106.40M | -66.98M |
| DilutedAverageShares | 90.32M | 73.81M | 60.80M | 31.66M |
| BasicAverageShares | 90.32M | 73.81M | 60.80M | 31.66M |
| DilutedEPS | -1.65 | -1.38 | -1.64 | -2.11 |
| BasicEPS | -1.65 | -1.38 | -1.64 | -2.11 |
| DilutedNIAvailtoComStockholders | -149.10M | -102.07M | -99.42M | -66.92M |
| NetIncomeCommonStockholders | -149.10M | -102.07M | -99.42M | -66.92M |
| NetIncome | -149.10M | -102.07M | -99.42M | -66.92M |
| NetIncomeIncludingNoncontrollingInterests | -149.10M | -102.07M | -99.42M | -66.92M |
| NetIncomeContinuousOperations | -149.10M | -102.07M | -99.42M | -66.92M |
| TaxProvision | -9.00K | 193.00K | 70.00K | 321.00K |
| PretaxIncome | -149.11M | -101.88M | -99.35M | -66.60M |
| OtherIncomeExpense | 17.50M | 14.18M | 7.05M | 377.00K |
| OtherNonOperatingIncomeExpenses | 17.50M | 14.18M | 7.18M | -1.21M |
| SpecialIncomeCharges | 0.00 | 1.58M | ||
| OtherSpecialCharges | -1.58M | |||
| GainOnSaleOfSecurity | -6.00K | -133.00K | ||
| NetNonOperatingInterestIncomeExpense | 140.00K | |||
| InterestExpenseNonOperating | 8.00K | |||
| InterestIncomeNonOperating | 148.00K | |||
| OperatingIncome | -166.62M | -116.06M | -106.40M | -66.98M |
| OperatingExpense | 176.61M | 150.54M | 120.25M | 76.58M |
| ResearchAndDevelopment | 130.15M | 112.08M | 82.23M | 52.26M |
| SellingGeneralAndAdministration | 46.46M | 38.46M | 38.02M | 24.32M |
| GeneralAndAdministrativeExpense | 46.46M | 38.46M | 38.02M | 24.32M |
| OtherGandA | 46.46M | 38.46M | 38.02M | 24.32M |
| TotalRevenue | 9.99M | 34.48M | 13.85M | 9.60M |
| OperatingRevenue | 9.99M | 34.48M | 13.85M | 9.60M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 92.38M | 88.45M | 61.03M | 60.26M |
| ShareIssued | 92.38M | 88.45M | 61.03M | 60.26M |
| TotalDebt | 26.49M | 27.11M | 27.75M | 0.00 |
| TangibleBookValue | 252.95M | 368.40M | 300.87M | 387.82M |
| InvestedCapital | 252.95M | 368.40M | 300.87M | 387.82M |
| WorkingCapital | 188.73M | 310.54M | 232.12M | 365.36M |
| NetTangibleAssets | 252.95M | 368.40M | 300.87M | 387.82M |
| CapitalLeaseObligations | 26.49M | 27.11M | 27.75M | 0.00 |
| CommonStockEquity | 252.95M | 368.40M | 300.87M | 387.82M |
| TotalCapitalization | 252.95M | 368.40M | 300.87M | 387.82M |
| TotalEquityGrossMinorityInterest | 252.95M | 368.40M | 300.87M | 387.82M |
| StockholdersEquity | 252.95M | 368.40M | 300.87M | 387.82M |
| GainsLossesNotAffectingRetainedEarnings | 255.00K | 30.00K | -1.52M | -135.00K |
| RetainedEarnings | -448.39M | -299.29M | -197.22M | -97.79M |
| AdditionalPaidInCapital | 701.08M | 667.65M | 499.60M | 485.75M |
| CapitalStock | 9.00K | 8.00K | 6.00K | 6.00K |
| CommonStock | 9.00K | 8.00K | 6.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 60.36M | 63.81M | 72.89M | 54.53M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 29.71M | 35.51M | 44.77M | 28.70M |
| OtherNonCurrentLiabilities | 785.00K | 2.94M | 1.65M | 4.10M |
| NonCurrentDeferredLiabilities | 3.87M | 6.66M | 16.34M | 24.61M |
| NonCurrentDeferredRevenue | 3.32M | 6.10M | 15.95M | 22.03M |
| NonCurrentDeferredTaxesLiabilities | 548.00K | 557.00K | 381.00K | 476.00K |
| LongTermDebtAndCapitalLeaseObligation | 25.06M | 25.91M | 26.78M | 0.00 |
| LongTermCapitalLeaseObligation | 25.06M | 25.91M | 26.78M | 0.00 |
| CurrentLiabilities | 30.65M | 28.30M | 28.13M | 25.83M |
| OtherCurrentLiabilities | 1.66M | 1.11M | 1.37M | 788.00K |
| CurrentDeferredLiabilities | 3.13M | 2.85M | 9.94M | 8.70M |
| CurrentDeferredRevenue | 3.13M | 2.85M | 9.94M | 8.70M |
| CurrentDebtAndCapitalLeaseObligation | 1.43M | 1.20M | 966.00K | |
| CurrentCapitalLeaseObligation | 1.43M | 1.20M | 966.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.56M | 9.52M | 5.75M | 4.22M |
| PayablesAndAccruedExpenses | 15.88M | 13.63M | 10.10M | 12.11M |
| CurrentAccruedExpenses | 13.40M | 10.51M | 8.96M | 8.12M |
| Payables | 2.48M | 3.12M | 1.15M | 3.99M |
| AccountsPayable | 2.48M | 3.12M | 1.15M | 3.99M |
| TotalAssets | 313.31M | 432.21M | 373.76M | 442.36M |
| TotalNonCurrentAssets | 93.94M | 93.37M | 113.52M | 51.16M |
| OtherNonCurrentAssets | 5.52M | 1.59M | 1.54M | 975.00K |
| InvestmentsAndAdvances | 49.12M | 51.33M | 77.07M | 45.30M |
| InvestmentinFinancialAssets | 49.12M | 51.33M | 77.07M | 45.30M |
| AvailableForSaleSecurities | 49.12M | 51.33M | 77.07M | 45.30M |
| NetPPE | 39.29M | 40.45M | 34.91M | 4.89M |
| AccumulatedDepreciation | -12.88M | -9.14M | -5.65M | -4.08M |
| GrossPPE | 52.17M | 49.60M | 40.56M | 8.96M |
| Leases | 11.52M | 2.23M | 1.88M | 1.70M |
| ConstructionInProgress | 0.00 | 8.20M | 993.00K | 9.00K |
| OtherProperties | 39.06M | 37.76M | 36.82M | 6.85M |
| MachineryFurnitureEquipment | 1.59M | 1.39M | 870.00K | 406.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 219.38M | 338.84M | 260.25M | 391.19M |
| OtherCurrentAssets | 1.78M | 1.22M | 1.12M | 671.00K |
| PrepaidAssets | 4.81M | 4.93M | 6.80M | 6.57M |
| Receivables | 3.25M | 3.86M | 4.66M | 8.12M |
| OtherReceivables | 2.06M | 3.01M | 3.89M | 6.75M |
| AccruedInterestReceivable | 930.00K | 702.00K | 570.00K | 226.00K |
| AccountsReceivable | 265.00K | 148.00K | 202.00K | 1.15M |
| CashCashEquivalentsAndShortTermInvestments | 209.54M | 328.83M | 247.66M | 375.83M |
| OtherShortTermInvestments | 193.24M | 277.67M | 189.32M | 135.41M |
| CashAndCashEquivalents | 16.29M | 51.16M | 58.34M | 240.42M |
| CashEquivalents | 16.29M | 51.16M | 58.34M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -144.71M | -104.90M | -98.02M | -35.64M |
| RepaymentOfDebt | 0.00 | -119.00K | ||
| IssuanceOfDebt | 0.00 | 1.15M | ||
| IssuanceOfCapitalStock | 15.19M | 152.72M | 0.00 | 429.85M |
| CapitalExpenditure | -6.50M | -11.61M | -7.05M | -3.12M |
| IncomeTaxPaidSupplementalData | 0.00 | 170.00K | 0.00 | 11.00K |
| EndCashPosition | 16.34M | 51.21M | 58.38M | 240.47M |
| BeginningCashPosition | 51.21M | 58.38M | 240.47M | 15.95M |
| ChangesInCash | -34.87M | -7.18M | -182.08M | 224.51M |
| FinancingCashFlow | 16.72M | 154.30M | 2.13M | 433.43M |
| CashFlowFromContinuingFinancingActivities | 16.72M | 154.30M | 2.13M | 433.43M |
| ProceedsFromStockOptionExercised | 1.53M | 1.58M | 2.13M | 2.55M |
| NetPreferredStockIssuance | 0.00 | 108.83M | ||
| PreferredStockIssuance | 0.00 | 108.83M | ||
| NetCommonStockIssuance | 15.19M | 152.72M | 0.00 | 321.02M |
| CommonStockIssuance | 15.19M | 152.72M | 0.00 | 321.02M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.03M | ||
| NetLongTermDebtIssuance | 0.00 | 1.03M | ||
| LongTermDebtPayments | 0.00 | -119.00K | ||
| LongTermDebtIssuance | 0.00 | 1.15M | ||
| InvestingCashFlow | 86.61M | -68.18M | -93.25M | -176.40M |
| CashFlowFromContinuingInvestingActivities | 86.61M | -68.18M | -93.25M | -176.40M |
| NetInvestmentPurchaseAndSale | 93.10M | -56.57M | -86.19M | -173.28M |
| SaleOfInvestment | 397.49M | 338.19M | 252.87M | 0.00 |
| PurchaseOfInvestment | -304.39M | -394.76M | -339.06M | -173.28M |
| NetIntangiblesPurchaseAndSale | -1.62M | 0.00 | -600.00K | -1.00M |
| PurchaseOfIntangibles | -1.62M | 0.00 | -600.00K | -1.00M |
| NetPPEPurchaseAndSale | -4.87M | -11.61M | -6.45M | -2.12M |
| SaleOfPPE | 13.00K | 0.00 | 0.00 | |
| PurchaseOfPPE | -4.88M | -11.61M | -6.45M | -2.12M |
| OperatingCashFlow | -138.20M | -93.29M | -90.97M | -32.52M |
| CashFlowFromContinuingOperatingActivities | -138.20M | -93.29M | -90.97M | -32.52M |
| ChangeInWorkingCapital | -5.11M | -7.32M | -4.20M | 29.07M |
| ChangeInOtherWorkingCapital | -2.51M | -16.77M | -4.94M | 31.13M |
| ChangeInOtherCurrentLiabilities | -621.00K | -637.00K | -418.00K | -162.00K |
| ChangeInOtherCurrentAssets | -3.94M | -48.00K | -564.00K | -316.00K |
| ChangeInPayablesAndAccruedExpense | 1.78M | 7.56M | -768.00K | 5.42M |
| ChangeInAccruedExpense | 2.13M | 5.74M | 1.95M | 4.28M |
| ChangeInPayable | -354.00K | 1.82M | -2.72M | 1.14M |
| ChangeInAccountPayable | -354.00K | 1.82M | -2.72M | 1.14M |
| ChangeInPrepaidAssets | -433.00K | 1.77M | -975.00K | -4.04M |
| ChangeInReceivables | 608.00K | 805.00K | 3.46M | -2.96M |
| ChangesInAccountReceivables | -117.00K | 54.00K | 951.00K | -1.00M |
| OtherNonCashItems | 10.00K | 3.27M | -15.00K | 2.43M |
| StockBasedCompensation | 16.71M | 13.75M | 11.72M | 3.45M |
| UnrealizedGainLossOnInvestmentSecurities | 111.00K | 6.00K | 133.00K | 0.00 |
| AmortizationOfSecurities | -4.73M | -4.42M | -797.00K | 52.00K |
| DepreciationAmortizationDepletion | 3.93M | 3.52M | 1.62M | 984.00K |
| DepreciationAndAmortization | 3.93M | 3.52M | 1.62M | 984.00K |
| OperatingGainsLosses | -9.00K | -34.00K | -1.57M | |
| GainLossOnSaleOfPPE | -9.00K | -34.00K | 0.00 | 4.00K |
| NetIncomeFromContinuingOperations | -149.10M | -102.07M | -99.42M | -66.92M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRBU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|